Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 10, 2025, titled ""Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38xBCMAxCD3 Trispecific Antibody"".